肿瘤坏死因子α抑制剂诱导的银屑病研究进展

doi:10.35541/cjd.20200251

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (9): 821-824.doi: 10.35541/cjd.20200251

肿瘤坏死因子α抑制剂诱导的银屑病研究进展

孙杰王睿李承新

解放军总医院第一医学中心皮肤科，北京 100853

收稿日期:2020-03-13 修回日期:2021-01-07 发布日期:2022-09-02
通讯作者: 李承新 E-mail:chengxinderm@163.com
基金资助:
国家自然科学基金（81972936）；首都临床特色应用研究项目（Z181100001718038）；解放军总医院科技创新苗圃基金（18KMM10）

Tumor necrosis factor-α inhibitor?induced psoriasis

Sun Jie, Wang Rui, Li Chengxin

Department of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

Received:2020-03-13 Revised:2021-01-07 Published:2022-09-02
Contact: Li Chengxin E-mail:chengxinderm@163.com
Supported by:
National Natural Science Foundation of China（81972936）; Capital Clinical Characteristic Application Research （Z181100001718038）; Science and Technology Innovation Nursery Fund of Chinese PLA General Hospital （18KMM10）

摘要/Abstract

摘要： 【摘要】近年来肿瘤坏死因子α（TNF-α）抑制剂用于治疗多种炎症性疾病取得显著疗效，但同时也出现了一种不容忽视的、矛盾的药物不良反应，即其可诱发部分患者出现银屑病样表现，称之为TNF-α抑制剂诱导的银屑病，病理表现可为银屑病样改变，也可为海绵状改变，发病机制可能与TNF-α和Ⅰ型干扰素之间平衡失调、白细胞介素23/Th17细胞轴参与、感染有关。本文对TNF-α抑制剂诱导的银屑病的流行病学、组织学特征及其可能的发病机制做一阐述，为识别和治疗TNF-α抑制剂诱导的银屑病提供依据。

关键词: 银屑病, 肿瘤坏死因子α, 生物制剂, 不良反应, 肿瘤坏死因子α抑制剂诱导的银屑病

Abstract: 【Abstract】 Tumor necrosis factor-α （TNF-α） inhibitors have been widely used and proven to be effective in the treatment of various inflammatory disorders in recent years, but there is a noteworthy and paradoxical adverse drug reaction that cannot be ignored, that is, TNF-α inhibitor-induced psoriasis. Its pathological manifestations could be psoriasiform or spongiotic changes, and its pathogenesis may be related to the imbalance between TNF-α and type Ⅰinterferon, the involvement of interleukin-23/T helper 17 axis, or infection. This review elaborates the epidemiological, histopathological features and possible pathogenesis of TNF-α inhibitor-induced psoriasis, and provides a basis for recognition and treatment of TNF-α inhibitor-induced psoriasis.

Key words: Psoriasis, Tumor necrosis factor-alpha, Biological agents, Adverse reactions, Tumor necrosis factor-α inhibitor-induced psoriasis

孙杰王睿李承新. 肿瘤坏死因子α抑制剂诱导的银屑病研究进展[J]. 中华皮肤科杂志, 2022,55(9):821-824. doi:10.35541/cjd.20200251

Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824.doi:10.35541/cjd.20200251

参考文献 38

［1］	Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti⁃tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study［J］. Ann Intern Med, 2016,164（1）:10⁃22. doi: 10.7326/M15⁃0729.
［2］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.
［3］	Mazloom SE, Yan D, Hu JZ, et al. TNF⁃α inhibitor⁃induced psoriasis: a decade of experience at the cleveland clinic［J］. J Am Acad Dermatol, 2020,83（6）:1590⁃1598. doi: 10.1016/j.jaad. 2018.12.018.
［4］	Montolio Chiva L, Martínez FÀ, Mateu Puchades A, et al. Psoriasis induced by biological therapy［J］. Reumatol Clin, 2020,4:S1699⁃258X（20）30019⁃X. doi: 10.1016/j.reuma.2019. 12.005.
［5］	Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn′s disease⁃associated spondyloarthropathy［J］. Rheumatol Int, 2018,38（7）:1297⁃1299. doi: 10.1007/s00296⁃018⁃4034⁃0.
［6］	Verea MM, Del Pozo J, Yebra⁃Pimentel MT, et al. Psoriasiform eruption induced by infliximab［J］. Ann Pharmacother, 2004,38（1）:54⁃57. doi: 10.1345/aph.1C477.
［7］	Brown G, Wang E, Leon A, et al. Tumor necrosis factor⁃α inhibitor⁃induced psoriasis: systematic review of clinical features, histopathological findings, and management experience［J］. J Am Acad Dermatol, 2017,76（2）:334⁃341. doi: 10.1016/j.jaad.2016.08.012.
［8］	单芳芳. TNF⁃α拮抗剂诱发或加重银屑病的临床特征与处理［D］. 苏州: 苏州大学, 2019. doi：10.27351/d.cnki.gszhu.2019. 001331.
［9］	李高洁, Krista Shrestha, 马文婷, 等. 阿达木单抗诱发银屑病样皮炎1例［J］. 中国皮肤性病学杂志, 2019,33（12）:1416⁃1418. doi: 10.13735/j.cjdv.1001⁃7089.201901121.
［10］	Guerra I, Pérez⁃Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti⁃TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study［J］. Inflamm Bowel Dis, 2016,22（4）:894⁃901. doi: 10.1097/MIB.0000000000000757.
［11］	Guerra I, Algaba A, Pérez⁃Calle JL, et al. Induction of psoriasis with anti⁃TNF agents in patients with inflammatory bowel disease: a report of 21 cases［J］. J Crohns Colitis, 2012,6（5）:518⁃523. doi: 10.1016/j.crohns.2011.10.007.
［12］	Groth D, Perez M, Treat JR, et al. Tumor necrosis factor⁃α inhibitor⁃induced psoriasis in juvenile idiopathic arthritis patients［J］. Pediatr Dermatol, 2019,36（5）:613⁃617. doi: 10.1111/pde.13859.
［13］	Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease［J］. J Pediatr Gastroenterol Nutr, 2019,69（2）:189⁃193. doi: 10.1097/MPG.0000000000002349.
［14］	Sondermann W, Herz S, Sody E, et al. Dermatological complications of therapy with biologics in inflammatory autoimmune diseases［J］. J Dtsch Dermatol Ges, 2019,17（10）:1029⁃1037. doi: 10.1111/ddg.13964.
［15］	Harrison MJ, Dixon WG, Watson KD, et al. Rates of new⁃onset psoriasis in patients with rheumatoid arthritis receiving anti⁃tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register［J］. Ann Rheum Dis, 2009,68（2）:209⁃215. doi: 10.1136/ard.2007.087288.
［16］	Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases［J］. Arthritis Care Res （Hoboken）, 2013, 65（12）: 2024⁃2031. doi: 10.1002/acr.22096.
［17］	Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti⁃tumor necrosis factor therapy: a paradoxical adverse reaction［J］. Arthritis Rheum, 2005,52（8）:2513⁃2518. doi: 10. 1002/art.21233.
［18］	Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis［J］. Semin Arthritis Rheum, 2010,40（3）:233⁃240. doi: 10.1016/j.semarthrit.2010.04.003.
［19］	Dalkilic E, Bulbul Baskan E, Alkis N, et al. Tumor necrosis factor⁃alpha antagonist therapy⁃induced psoriasis in Turkey: analysis of 514 patients［J］. Mod Rheumatol, 2012,22（5）:738⁃742. doi: 10.1007/s10165⁃011⁃0590⁃9.
［20］	孙婧, 张建中. 阿达木单抗治疗类风湿关节炎引起银屑病一例［J］. 中华皮肤科杂志, 2018,51（10）:760. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.015.
［21］	Aslanidis S, Pyrpasopoulou A, Douma S, et al. Tumor necrosis factor⁃a antagonist⁃induced psoriasis: yet another paradox in medicine［J］. Clin Rheumatol, 2008,27（3）:377⁃380. doi: 10. 1007/s10067⁃007⁃0789⁃5.
［22］	Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti⁃tumor necrosis factor alpha agents［J］. Pediatr Dermatol, 2017,34（3）:253⁃260. doi: 10.1111/pde. 13081.
［23］	Napolitano M, Balato N, Caso F, et al. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study［J］. Clin Exp Rheumatol, 2017,35（1）:137⁃140.
［24］	Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases［J］. Int J Dermatol, 2017,56（11）:1087⁃1102. doi: 10.1111/ijd.13691.
［25］	Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF⁃blockade therapy: a review and analysis of 127 cases［J］. J Dermatolog Treat, 2009,20（2）:100⁃108. doi: 10.1080/09546630802441234.
［26］	郭金竹, 王文慧, 叶珍珍, 等. 英夫利昔单抗治疗30例银屑病患者的疗效与安全性［J］. 中国皮肤性病学杂志, 2019,33（3）:265⁃269. doi: 10.13735/j.cjdv.1001⁃7089.201804074.
［27］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J/OL］. J Am Acad Dermatol, 2020,8:S0190⁃9622（20）33154⁃6［2021⁃01⁃28］. https://sci⁃hub.ren/10.1016/j.jaad.2020. 12.010. doi: 10.1016/j.jaad.2020. 12.010.
［28］	Hu JZ, Billings SD, Yan D, et al. Histologic comparison of tumor necrosis factor⁃α inhibitor⁃induced psoriasis and psoriasis vulgaris［J］. J Am Acad Dermatol, 2020,83（1）:71⁃77. doi: 10. 1016/j.jaad.2020.01.006.
［29］	Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis［J］. Clin Dermatol, 1998,16（3）:333⁃351. doi: 10.1016/s0738⁃081x（98）00005⁃4.
［30］	Hawryluk EB, Linskey KR, Duncan LM, et al. Broad range of adverse cutaneous eruptions in patients on TNF⁃alpha antagonists［J］. J Cutan Pathol, 2012,39（5）:481⁃492. doi: 10.1111/j.1600⁃0560.2012.01894.x.
［31］	Skrzeczynska⁃Moncznik J, Zabieglo K, Bossowski JP, et al. Eosinophils regulate interferon alpha production in plasmacytoid dendritic cells stimulated with components of neutrophil extracellular traps［J］. J Interferon Cytokine Res, 2017,37（3）:119⁃128. doi: 10.1089/jir.2016.0036.
［32］	Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis［J］. Nat Commun, 2018,9（1）:25. doi: 10.1038/s41467⁃017⁃02466⁃4.
［33］	Garcovich S, De Simone C, Genovese G, et al. Paradoxical skin reactions to biologics in patients with rheumatologic disorders［J］. Front Pharmacol, 2019,10:282. doi: 10.3389/fphar.2019.00 282.
［34］	Jean LB, Joseph LJ, Ronald PR, et al. Dermatology（皮肤病学）［M］. 朱学骏, 王宝玺, 孙建方, 等, 译. 北京: 北京大学医学出版社, 2014: 155.
［35］	Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF⁃α blockade shows immunological features typical of the early phase of psoriasis development［J］. J Pathol Clin Res, 2020,6（1）:55⁃68. doi: 10.1002/cjp2.147.
［36］	Mylonas A, Conrad C. Psoriasis: classical vs. paradoxical. The Yin⁃Yang of TNF and type i interferon［J］. Front Immunol, 2018,9:2746. doi: 10.3389/fimmu.2018.02746.
［37］	Bucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti⁃TNFα treatment: evaluation of disease⁃specific clinical and genetic markers［J/OL］. Int J Mol Sci, 2020,21（21）:7873［2020⁃01⁃28］. https://sci⁃hub.st/10.3390/ijms21217873. doi: 10.3390/ijms21217873.
［38］	Özkur E, Altunay İK, Leblebici C, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia［J］. Dermatol Ther, 2019,32（5）:e13033. doi: 10.1111/dth.13033.

[1]	肖春英王刚. 朗格汉斯细胞在银屑病中的作用研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 830-834.
[2]	刘晋沈征宇. 银屑病表观遗传调控的研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 825-829.
[3]	郑佳媛余炳前陈显侠骆志成. 成人寻常型银屑病瘙痒特征及对生活质量的影响调查[J]. 中华皮肤科杂志, 2022, 55(9): 790-794.
[4]	周雪, 余增洋, 陈有东, 郭春源, 于倩, 胡艺凡, 姚玲玲, 史玉玲, . 肿瘤坏死因子α介导银屑病脂肪酸去饱和酶2低表达[J]. 中华皮肤科杂志, 2022, 55(9): 752-758.
[5]	姚玲玲, 余增洋郭春源周静崔莲于倩虞英媛周雪蔡江鲁伊史玉玲, . 节律基因隐花色素2在银屑病小鼠模型及HaCaT细胞中的表达变化及机制研究[J]. 中华皮肤科杂志, 2022, 55(9): 759-766.
[6]	俞晨王刚. [开放获取] 小分子靶向药物：银屑病治疗的新选择[J]. 中华皮肤科杂志, 2022, 55(9): 747-751.
[7]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[8]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[9]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[10]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[11]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[12]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.
[13]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[14]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[15]	罗帅寒天龙海陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372.

肿瘤坏死因子α抑制剂诱导的银屑病研究进展

Tumor necrosis factor-α inhibitor?induced psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

Metrics

本文评价

推荐阅读 10